Transforming Rare Disease Treatment At Orphalan we identify, develop, and provide access to innovative treatments for patients with rare diseases to make a positive and meaningful difference.
| Website | https://www.orphalan.com |
| Revenue | $25.3 million |
| Employees | 139 (103 on RocketReach) |
| Address | 226, Boulevard Voltaire, Paris, Île-de-France 75011, FR |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Rare Disease Treatment, Rare Disease Therapies, Rare Disease Research, Orphan Drug Development, Pediatric Clinical Trials, Innovative Medicines, Genetic Disorders, Precision Medicine, Pharmaceutical Research, Drug Discovery, Personalized Therapies, Clinical Stage Development, Biopharmaceutical, Medical Innovation, New Drug Applications, Advanced Therapies, Clinical Trials, Healthcare Solutions, Patient Advocacy, Regulatory Affairs |
| Competitors | Sanofi, Bayer, Takeda, Regeneron, Amicus Therapeutics, Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Audentes Therapeutics, AVROBIO, Plexxikon Inc. +29 more (view full list) |
Looking for a particular Orphalan employee's phone or email?
The Orphalan annual revenue was $25.3 million in 2026.
Dmitry Paramonov is the President, US Operations of Orphalan.
103 people are employed at Orphalan.
Orphalan is based in Paris, Île-de-France.